---
title: "National development predicts government responses to the 2025 **PEPFAR** funding freeze"
id: "medrxiv-13-cross-national-factors-associated-with-governmental-responses-to-the-2025"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-cross-national-factors-associated-with-governmental-responses-to-the-2025"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.18.26365861v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# National development predicts government responses to the 2025 **PEPFAR** funding freeze
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-cross-national-factors-associated-with-governmental-responses-to-the-2025
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.18.26365861v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors classified Sub-Saharan African countries receiving **PEPFAR** support into three response levels: Level 1 (minimal/no response), Level 2 (partial response without resources/plans to fully offset losses), and Level 3 (high response with strategies to maintain services). - Final classification included 5 countries at Level 1, 10 at Level 2, and 14 at Level 3; these counts were reported in the source. - Investigators compared response level with national indicators: **Human Development Index** (HDI), GDP per capita, HIV prevalence, number of people living with HIV, annual HIV mortality, and historical PEPFAR funding. - The study used univariable proportional-odds ordinal logistic regression to evaluate associations between each country-level factor and response category. - Higher HDI showed a statistically significant positive association with stronger governmental response (OR = 4.05; 95% CI, 1.49–11.04; Holm-adjusted p = 0.0376) as reported by the authors. - GDP per capita (OR = 2.35; 95% CI, 1.00–5.51; unadjusted p = 0.0489) and HIV prevalence (OR = 3.53; 95% CI, 1.03–12.11; unadjusted p = 0.0452) were positively associated before multiple-comparison correction, but lost significance after Holm adjustment (adjusted p = 0.2261 for both). - Historical **PEPFAR** funding, total population living with HIV, and annual HIV mortality were not significantly associated with response level after adjustment, according to the manuscript. - The authors observed that several low-response countries were affected by active conflict or political instability, which may compound risk of treatment interruptions. - Data sources named in the paper include UNAIDS, UNDP HDR, IMF, **PEPFAR**, and the World Bank; full country-level variables and reviewer assessments are in the manuscript’s supporting files. - The study did not seek formal IRB review because it did not involve human subjects; the authors declared no competing interests.
## Clinical Analysis & Structured Key Points
Since its inception in 2003, the United States President's Emergency Plan for AIDS Relief (PEPFAR) has played a central role in HIV/AIDS prevention and treatment across Sub-Saharan Africa. Following the January 2025 suspension of United States foreign aid, which includes PEPFAR funding, countries across Sub-Saharan Africa demonstrated varying governmental responses to the resulting HIV funding disruptions. This study evaluates whether national characteristics were associated with a country's ability to respond to this funding crisis. Countries in Sub-Saharan Africa receiving PEPFAR funding were classified into one of three response categories: Level 1 (minimal or no governmental response), Level 2 (government response without sufficient plans or resources to fully offset funding losses), or Level 3 (high governmental response with strategies to maintain HIV/AIDS prevention and treatment services). Response categories were compared with national Human Development Index (HDI), GDP per capita, HIV prevalence, total population living with HIV, annual HIV mortality, and historical PEPFAR funding. Univariable proportional-odds ordinal logistic regression was used to identify factors associated with response level. Five countries (17.2%) were classified as Level 1, 10 (34.5%) as Level 2, and 14 (48.3%) as Level 3. Higher HDI was significantly associated with stronger governmental response (OR = 4.05; 95% CI, 1.49-11.04; Holm-adjusted p = 0.0376). GDP per capita (OR = 2.35; 95% CI, 1.00-5.51; unadjusted p = 0.0489) and HIV prevalence (OR = 3.53; 95% CI, 1.03-12.11; unadjusted p = 0.0452) demonstrated positive associations before adjustment for multiple comparisons, but neither remained significant after Holm correction (adjusted p = 0.2261 for both). Historical PEPFAR funding, total population living with HIV, and annual HIV mortality were not significantly associated with response level after adjustment. Countries with higher levels of human development demonstrated stronger governmental responses to the 2025 PEPFAR funding disruptions. Several countries with minimal documented responses were also affected by active conflict or political instability, potentially compounding their vulnerability to treatment interruptions. These findings suggest that broader national development may play an important role in governmental responses to funding disruptions and highlight the need to strengthen resilient health systems, diversify HIV financing, and prioritize support for countries at greatest risk of future funding shocks.
## Related Clinical Research

- [Global stakeholder priorities for point-of-care HIV NAATs: sensitivity, speed, and fingerstick sam](https://medichelpline.com/clinical-feed/plos-one-11-global-stakeholder-preferences-for-point-of-care-hiv-nucleic-acid-amplification.md)
- [Monitoring doxy-PEP impact: when to reassess guidance on STI prophylaxis](https://medichelpline.com/clinical-feed/plos-medicine-0-how-do-we-monitor-doxy-pep-impact-and-when-should-we-consider-revisiting.md)
- [Violence and HIV outcomes in female sex workers: global systematic review and meta-analysis](https://medichelpline.com/clinical-feed/plos-medicine-3-impact-of-violence-on-hiv-outcomes-among-female-sex-workers-a-global-systematic.md)
- [Diimide and Hydrazone Scaffolds as Novel LRAs for HIV-1 Shock-and-Kill Strategies](https://medichelpline.com/clinical-feed/pubmed-42735590.md) (DOI: 10.1016/j.bbrc.2026.154580)
- [Immunogenicity and structure of a stabilized HIV-1 clade C Env bound to an autologous bnAb — Front](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-immunogenicity-and-structure-of-a-stabilized-hiv-1-clade-c-env-from-a-pediatric.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.